188 related articles for article (PubMed ID: 37404105)
1. Prediction of Tumor Progression During Neoadjuvant Chemotherapy and Survival Outcome in Patients With Triple-Negative Breast Cancer.
Yoen H; Kim SY; Lee DW; Lee HB; Cho N
Korean J Radiol; 2023 Jul; 24(7):626-639. PubMed ID: 37404105
[TBL] [Abstract][Full Text] [Related]
2. Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy.
Kwon BR; Shin SU; Kim SY; Choi Y; Cho N; Kim SM; Yi A; Yun B; Jang M; Ha SM; Lee SH; Chang JM; Moon WK
Radiology; 2022 Aug; 304(2):310-319. PubMed ID: 35536129
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a nomogram based on pretreatment dynamic contrast-enhanced MRI for the prediction of pathologic response after neoadjuvant chemotherapy for triple-negative breast cancer.
Li Y; Chen Y; Zhao R; Ji Y; Li J; Zhang Y; Lu H
Eur Radiol; 2022 Mar; 32(3):1676-1687. PubMed ID: 34767068
[TBL] [Abstract][Full Text] [Related]
4. Predicting Axillary Response to Neoadjuvant Chemotherapy: Breast MRI and US in Patients with Node-Positive Breast Cancer.
Kim R; Chang JM; Lee HB; Lee SH; Kim SY; Kim ES; Cho N; Moon WK
Radiology; 2019 Oct; 293(1):49-57. PubMed ID: 31407967
[TBL] [Abstract][Full Text] [Related]
5. Predictive Clinicopathologic and Dynamic Contrast-Enhanced MRI Findings for Tumor Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Eom HJ; Cha JH; Choi WJ; Chae EY; Shin HJ; Kim HH
AJR Am J Roentgenol; 2017 Jun; 208(6):W225-W230. PubMed ID: 28350486
[TBL] [Abstract][Full Text] [Related]
6. Radiomics features based on automatic segmented MRI images: Prognostic biomarkers for triple-negative breast cancer treated with neoadjuvant chemotherapy.
Ma M; Gan L; Liu Y; Jiang Y; Xin L; Liu Y; Qin N; Cheng Y; Liu Q; Xu L; Zhang Y; Wang X; Zhang X; Ye J; Wang X
Eur J Radiol; 2022 Jan; 146():110095. PubMed ID: 34890936
[TBL] [Abstract][Full Text] [Related]
7. Is the presence of edema and necrosis on T2WI pretreatment breast MRI the key to predict pCR of triple negative breast cancer?
Harada TL; Uematsu T; Nakashima K; Sugino T; Nishimura S; Takahashi K; Hayashi T; Tadokoro Y; Watanabe J; Nakamoto S; Ito T
Eur Radiol; 2020 Jun; 30(6):3363-3370. PubMed ID: 32062698
[TBL] [Abstract][Full Text] [Related]
8. Multivariate machine learning models for prediction of pathologic response to neoadjuvant therapy in breast cancer using MRI features: a study using an independent validation set.
Cain EH; Saha A; Harowicz MR; Marks JR; Marcom PK; Mazurowski MA
Breast Cancer Res Treat; 2019 Jan; 173(2):455-463. PubMed ID: 30328048
[TBL] [Abstract][Full Text] [Related]
9. Mammographic density changes after neoadjuvant chemotherapy in triple-negative breast cancer: Association with treatment and survival outcome.
Choi Y; Kim SY; Cho N; Moon WK
Clin Imaging; 2024 May; 109():110136. PubMed ID: 38552382
[TBL] [Abstract][Full Text] [Related]
10. Prospective Evaluation of Ultrafast Breast MRI for Predicting Pathologic Response after Neoadjuvant Therapies.
Ramtohul T; Tescher C; Vaflard P; Cyrta J; Girard N; Malhaire C; Tardivon A
Radiology; 2022 Dec; 305(3):565-574. PubMed ID: 35880977
[TBL] [Abstract][Full Text] [Related]
11. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
[TBL] [Abstract][Full Text] [Related]
12. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choudhery S; Gomez-Cardona D; Favazza CP; Hoskin TL; Haddad TC; Goetz MP; Boughey JC
Acad Radiol; 2022 Jan; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
[TBL] [Abstract][Full Text] [Related]
13. Factors Affecting Pathologic Complete Response Following Neoadjuvant Chemotherapy in Breast Cancer: Development and Validation of a Predictive Nomogram.
Kim SY; Cho N; Choi Y; Lee SH; Ha SM; Kim ES; Chang JM; Moon WK
Radiology; 2021 May; 299(2):290-300. PubMed ID: 33754824
[TBL] [Abstract][Full Text] [Related]
14. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
15. Association between systemic immune-inflammation index and neoadjuvant chemotherapy efficacy as well as prognosis in triple-negative breast cancer.
Pang J; Wang S; Liao L; Liu X
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Sept 28; 46(9):958-965. PubMed ID: 34707005
[TBL] [Abstract][Full Text] [Related]
16. Predictors of Distant Metastases in Triple-Negative Breast Cancer Without Pathologic Complete Response After Neoadjuvant Chemotherapy.
Kennedy WR; Tricarico C; Gabani P; Weiner AA; Altman MB; Ochoa LL; Thomas MA; Margenthaler JA; Sanati S; Peterson LL; Ma CX; Ademuyiwa FO; Zoberi I
J Natl Compr Canc Netw; 2020 Mar; 18(3):288-296. PubMed ID: 32135512
[TBL] [Abstract][Full Text] [Related]
17. Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial.
Golshan M; Wong SM; Loibl S; Huober JB; O'Shaughnessy J; Rugo HS; Wolmark N; Ansell P; Maag D; Sullivan DM; Metzger-Filho O; Von Minckwitz G; Geyer CE; Sikov WM; Untch M
Eur J Surg Oncol; 2020 Feb; 46(2):223-228. PubMed ID: 31606288
[TBL] [Abstract][Full Text] [Related]
18. Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer.
Golden DI; Lipson JA; Telli ML; Ford JM; Rubin DL
J Am Med Inform Assoc; 2013; 20(6):1059-66. PubMed ID: 23785100
[TBL] [Abstract][Full Text] [Related]
19. Breast parenchymal signal enhancement ratio at preoperative magnetic resonance imaging: association with early recurrence in triple-negative breast cancer patients.
Park VY; Kim EK; Kim MJ; Yoon JH; Moon HJ
Acta Radiol; 2016 Jul; 57(7):802-8. PubMed ID: 26516288
[TBL] [Abstract][Full Text] [Related]
20. Pretreatment MR Imaging Features of Triple-Negative Breast Cancer: Association with Response to Neoadjuvant Chemotherapy and Recurrence-Free Survival.
Bae MS; Shin SU; Ryu HS; Han W; Im SA; Park IA; Noh DY; Moon WK
Radiology; 2016 Nov; 281(2):392-400. PubMed ID: 27195438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
